Form 4: Director Michael Miller Receives Rigel Stock Grant

Rigel Pharmaceuticals director Michael Patrick Miller acquired 5,750 shares of common stock via a restricted stock unit award.

Summary

• Director Michael Patrick Miller was granted 5,750 restricted stock units (RSUs) by Rigel Pharmaceuticals, Inc.
• The shares were acquired at a price of $0 per share as part of a compensation award.
• Following this transaction, the director's total beneficial ownership of common stock increased to 5,937 shares.
• The RSUs are scheduled to vest on the date prior to the company's next annual meeting, contingent upon continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting of the award is subject to the director's continuous service on the Board of Directors.

Future Outlook

The restricted stock units will vest on the day prior to the company's next annual meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-cap pharmaceutical companies.
• The vesting schedule tied to the annual meeting is a common retention mechanism for board members in the industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 5,750 restricted stock units prior to the next annual meeting.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Director Compensation, Restricted Stock Units